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Abstract
Introduction: Noncompliance with healthcare undoubtedly has a strong influence on the high prevalence of uncontrolled obstruc-
tive diseases. The aim of our study was to evaluate the quality of medical conduct in patients with asthma or chronic obstructive 
lung diseases (COPD), with encompassed two-levelled system of health care. 
Material and methods: A survey of general practitioners (GP), allergists and pulmonologists practicing in Poland was performed 
between September and December 2016.
The basic survey included the data concerning the number of treated patients, the course of the visits, treatment regimens and 
whether the patients follow the instructions of the physician. The specialist survey recorded the details of the specialist visits, 
their frequency and character, an evaluation of the pharmacological and non-pharmacological therapies and an evaluation of the 
GP’s actions.
Results: The basic questionnaire was completed by 807 doctors with an average of 21 ± 9.85 years of medical experience. Most 
of the interviewed individuals were GPs (56%), followed by pulmonologists (28%) and allergists (16%).
The GP reported 47 cases/month with obstructive pulmonary conditions, including 48.94% asthma and 51.06% COPD patients. 
They diagnosed three new asthma and COPD patients per month. The allergists treated patients with asthma (105 patients/ 
/month), with 19 newly-diagnosed patients/month. The pulmonologists treated fewer asthma cases than COPD: 71 and 98 pa-
tients respectively. They reported 14 patients/month of newly-diagnosed COPD cases. The patients took inhaled glucocorticoids 
and long-acting b adrenoceptor agonists in separate inhalers. The most frequently-used device was a disc. In opinion of the 
specialists, half of the therapies initiated recently by GPs for patients with asthma and COPD required modifications. 
Conclusions: There is a disparity between the true state of medical care of asthma and COPD patients and globally-accepted 
standards.
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Introduction
The Epidemiology of Allergic Diseases in 
Poland (ECAP) study reports the incidence rate 
for asthma in recent years in Poland to be 9.54% 
in adults, and 11% in children [1]. In contrast, 
the analogous rates in the whole of the European 
Union are estimated to be 8.2 % among adults 
and 9.2% in children [2]. Chronic obstructive 
pulmonary disease (COPD) is most commonly 
caused by active rather than passive exposure to 
tobacco smoke, and mainly affects people aged 40 
years or more. The prevalence of COPD in Poland 
is estimated at 9.3% of the population [3]. 
Although a systematic increase in the number 
of COPD and asthma patients was observed in the 
late XX century [1–3], the last decade has seen 
a stabilisation of this incidence rate [4, 5]. The 
practical and social costs associated with these 
two conditions remain high, especially in regard 
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to patients with severe asthma, or those with 
frequent exacerbator phenotype suffering from 
COPD [4, 5]. It is important to mention that ac-
cording to the World Health Organisation (WHO) 
and the Global Initiative for chronic Obstructive 
Lung Disease (GOLD), COPD is also projected to 
become the third leading cause of death in the 
global population in 2020 [5]. 
Medical conduct, both treatment and prophy-
lactic, is highly imperfect. This has been generally 
attributed to a combination of inadequate public 
awareness and ignorance on the part of the health 
care authorities. In 2013, only 3% of adults in Po-
land were aware of the existence of the conditions 
referred to as COPD [6].
Noncompliance with healthcare is undoubt-
edly a serious reason behind the high prevalence 
of uncontrolled or incompletely controlled asth-
ma, which was shown in 50% of adults and 70% 
of children [1, 7]. Kardas et al. [8] report that 83% 
of patients suffering from chronic conditions dis-
continue pharmacotherapy without medical con-
sultation. The material costs of such a decision, 
including intermediate costs such as disabilities, 
are significantly higher than state expenditures 
associated with therapies for chronic condi-
tions. A combined effort by the doctor, mid-level 
medi cal personnel, patient and patient’s family 
is clearly required for effective medical care 
[3, 6, 8–11]. Although a wealth of literature exists 
which is devoted to this aim, the number of guide-
books and schools for patients and their families 
remains low [12]. There is limited evidence of 
effective training being provided for patients, or 
direct instruction being given by physicians: what 
little information is given seems to be minimally 
effective [13]. The knowledge possessed by the 
doctors and its regular updating, appear to be also 
imperfect [13]. Several such studies highlight the 
need for diligent and systematic training of the 
medical and paramedical personnel [2, 3, 6, 13]. 
One of the significant issues associated with 
public health is the absence of unambiguous 
standards concerning the diversified role of gen-
eral practitioners (GP) and specialists regarding 
COPD. This relationship has direct implications 
not only on the national budget, but mainly on the 
effectiveness of treating individual patients [2, 3, 
6, 7, 11]. Therefore, the present study evaluates 
the quality of medical treatment provided for 
these groups of patients, with a two-level system 
of health care. It examines the significance of se-
lected parameters which in our experience, have 
a particularly strong influence on the quality of 
medical treatment. 
Material and methods
The study was performed between Sep-
tember 2016 and December 2016. A survey was 
performed of a number of general practitioners 
(GP), allergists and pulmonologists practising in 
the following Polish voivodships: Lodz, Masovia, 
Lesser Poland, Silesia, Lower Silesia, Kuyavia-Po-
merania, West Pomerania, Lublin, Lubusz, Opole, 
Subcarpathia, Pomerania, Swietokrzyskie, Var-
mia-Masuria and Greater Poland.
The online questionnaires were completed by 
qualified interviewers during the course of four or 
six visits. All interviewers were trained for all the 
formal, legal and technical aspects of the research. 
The first visit involved the initial enrolment, with 
the inclusion criteria being clinicians willing to 
participate in the study, possessing a minimum of 
five years of experience in working with asthma 
and COPD patients, and a minimum of 10 pa-
tients with obstructive pulmonary diseases. The 
following three visits involved a so-called basic 
mode survey, which obtained data concerning the 
number of treated asthma patients, the course of 
the visits, treatment regimens and whether the 
patients follow the instructions. The advanced 
mode survey was designed for specialists expe-
rienced in chronic respiratory disorders and for 
allergists. The questions concerned the details of 
the specialist visits, their frequency, character, the 
evaluation of the pharmacological and non-phar-
macological therapies in asthma cases, COPD and 
evaluation of treatment by the GP. 
The data was presented as absolute values 
and as percentages. The central tendency was 
measured by arithmetic mean and median. As 
a measure of spread, standard deviation was used. 
Analysis was performed by Kantar TNS company.
Results
The basic questionnaire was completed by 
807 doctors with an average of 21 ± 9.85 years 
of medical experience. Most of the interviewed 
individuals were GPs (n = 454; 56%), followed 
by pulmonologists (n = 223; 28%), and then 
allergists (n = 130; 16%). Most of those inter-
viewed were public health care clinicians (64%). 
During the following two visits, 72 allergists and 
123 pulmonologists completed the advanced 
questionnaires. Figure 1 presents the number of 
participating doctors according to voivodship. 
GPs reported a  relatively small number of 
patients with obstructive pulmonary conditions: 
approximately 47 cases a month, including 23 
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Figure 1. The number of participating doctors from particular voivod-
ships
Figure 2. Comorbities in patients with COPD ad astma 
(48.94%) asthma and 24 (51.06%) COPD patients. 
They also reported typically three new diagnoses 
of asthma and COPD during the course of one 
month.
Allergists treat mainly patients with asthma 
(105 patients/month), with a relatively high num-
ber of newly-diagnosed individuals (19 patients/ 
/month). In contrast, the pulmonologists treated 
fewer asthma cases than COPD: 71 and 98 pa-
tients, respectively. These specialists reported 
a high number of newly-diagnosed COPD cases: 
14 patients/month. 
The survey identified comorbidities in both 
populations of patients (Fig. 2).
It was found that 98% of specialised depart-
ments were capable of performing spirometry 
including the reversibility test. However, 56% of 
GP clinics was capable of performing spirometry. 
Only 2% of respiratory specialists reported that 
these tests could not be provided.
Otherwise, spirometry was reported as being 
performed at least once a year in patients with 
COPD: least commonly in GP clinics (62%). Only 
8% of asthma patients have undergone peak ex-
piratory flow rate (PEFR) measurement. Between 
12–16% of asthma patients and 9% of COPD pa-
tients discontinued medical treatment without 
an authorized reason (Fig. 3).
The majority of patients took the medications 
in separate inhalers, which included inhaled 
glucocorticoids (ICS) (427 patients — 26%) and 
long-acting b adrenoceptor agonists (LABA) 
(358 patients — 22.4%) (Fig. 4). The most com-
monly-used ICS in an individual inhaler was 
budesonide, and the most common LABA was 
formoterol. The use of combined medications in 
a single device was marginally less common (362 
patients — 22.4%) and mainly involved salmet-
erol and fluticasone. Additionally, muscarinic 
receptor antagonist (LAMA) were used in 72 pa-
tients (4.8%) (Table1). Inhalation treatment was 
most commonly (80%) prescribed for two to three 
months. All three groups of respondents reported 
that the most frequently-used device was the disc: 
dry powder in multi-unit dose inhaler (Fig. 5).
The majority of allergists (97%), pulmonol-
ogists (95%) and GPs (83%) declared systematic 
verifications of the correct use of the inhalers by 
the patients. During the appointments, training 
in the use of the inhalers was estimated to last 
approximately five minutes for asthma patients, 
and six minutes for the COPD patients. Figure 
6 presents the frequency of the verifications of 
device usage. 
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Figure 3. Compliance of the therapy according to diseases and doctors’ specialization
Figure 4. The percentage of patients taking two formulations in one 
device
Figure 5. The percentage of patients who use disc
Figure 6. The frequency of control of the appropriate device usage
The results also indicated that 85% of al-
lergists, 83% of pulmonologists and 70% of GPs 
stated that the nurses cooperating with them are 
entirely capable of delivering the appropriate 
instructions for the use of inhalers. Respectively, 
6%, 11% and 14% admitted that the mid-level 
medical personnel they work with were not able 
to provide such information. Additionally, 17% 
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of allergists, 13% pulmonologists and 7% of GPs 
reported always asking the nurse to perform this 
function. 
Mistakes and imperfections in the appro-
priate use of the medications were found in 
approximately 19% of cases. A small percentage 
of patients (10%) were found to be using the disc 
inhaler incorrectly. Handouts or a demonstration 
device would be valuable aids to educating the 
patient in the correct usage of the inhaler. About 
6% of the interviewees agree that internet resour-
ces or patient meetings may be helpful.
The doctors of all three groups together con-
cluded that over 90% of their patients follow the 
treatment regime regularly, with only sporadic 
errors. The breathing exercises are applied in 15% 
of COPD patients. 
In opinion of the doctors specialising in 
respiratory conditions, half of the therapies 
recommended recently by GPs for patients with 
asthma and COPD require modifications. The spe-
cialists also report applying changes in treatment 
prescribed by GPs in 56% of cases. The majority 
of specialised doctors (88%) provide therapeutic 
recommendations for GPs. 
Discussion 
The study gathered results from all voivod-
ships in Poland, and so can be treated as repre-
sentative of the entire country. 
As the study was performed in late 2016, 
the conduct of the medical professionals could 
not be assessed with regard to the subsequently 
published GOLD 2017 guidelines [5]. However, 
it is important to highlight that the questions in-
cluded in the surveys did not involve the details 
concerning the application of the medications, 
but rather the general rules governing their usage. 
Moreover, the guidelines do not recommend new 
pharmacotherapy standards for the medications 
used in 2010–2016 [4, 5]. 
In specialised clinics, obstructive pulmonary 
conditions are usually treated in a continuous 
manner. This treatment routine diverges from 
the official standards and actual health needs. 
GOLD guidelines concerning the prophylaxis and 
treatment of COPD, state that mild stages of the 
diseases and their mild exacerbations should be 
treated by GPs [1, 2, 4, 5]. It is estimated that 85% 
of all asthma cases are the mild type [4]. Although 
detailed diagnostics and cases of exacerbations 
require consultation with a respiratory specialist, 
GPs should be able to handle mild asthma cases 
with appropriate basic medical conduct [4]. This 
disparity between the requirements and reality 
may account for the occurrence of undiagnosed 
cases and the application of inappropriate treat-
ment [1–11, 13]. 
Some interesting results were obtained re-
garding testing. As the performance of spirometry 
tests in groups of patients at higher risk could sig-
nificantly improve the identification of COPD [10], 
it is clear that GPs should be equipped and com-
prehensively educated in spirometry testing tech-
niques. However, a disturbing finding was that 56% 
of surveyed clinics and 2% of specialised clinics 
do not perform reversibility tests, a finding that 
makes the validity of most diagnoses questionable. 
Comorbidities identified in Polish population 
appear to be comparable with data obtained from 
global studies. Cardiovascular system disorders, 
diabetes, metabolic syndrome and obesity impair 
the general condition of the patient and worsen 
the prognosis of obstructive lung diseases [4, 5, 9]. 
Overlapping features of asthma and COPD were 
identified in 5% of the Polish population; how-
ever, this prevalence was found to range from 
2.1 to 51% across the world, depending on study 
criterion and country [14]. 
An analysis of the general population of the 
Lodz voivodeship in 1998–2000 showed that 
48% of adult asthma patients had discontinued 
the intake of anti-asthmatic medications in the 
previous 12 months. The individuals suffering 
from asthma in the previous 12 months had 
most commonly been prescribed LABA (46.8%), 
SAMA/SABA (13%), ICS (36.4%), oral glucocorti-
coids (16.9%), parenteral glucocorticoids (3.9%), 
xanthines (33.8%) and chromones (11.7%) [7]: 
the administration of inhaled glucocorticoids 
was relatively low compared to the surprisingly 
frequent chronic administration of xanthines 
and chromones, suggesting that over half of the 
patient population received medications contrary 
to the official standards [4, 7].
Although another study conducted in 2016 
also indicated prevalent use of ICS, it did not 
record xanthine or chromone use, which may 
suggest closer compliance with official standards 
[4]. It is important to note that 22.6% of inter-
viewed doctors in the present study prescribed 
the use of combined inhaled glucocorticoids and 
LABA, which is highly recommended by global 
opinion-forming organisations and confirmed by 
several studies [4, 5, 14, 15]. However, the major-
ity of asthma cases are mild, allowing the basic 
application of ICS alone, with the option of dose 
manipulation [4]. Although our study did not in-
clude the severity of asthma, the data concerning 
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the percentage of the mild asthma cases revealed 
doubts behind the prevalent use of the combined 
method [4]. Assuming that recommendations 
existed for the chronic use of combined inhaled 
glucocorticoids and LABA administration, the 
medications would have to be administrated 
together in most cases, via a single inhaler [4, 5, 
15, 16]. However, it was identified that in Poland 
these medications are applied separately. 
The low rate of LAMA application appears 
to be associated partly with the difficulties as-
sociated with reimbursing this group of drugs 
in 2016 in Poland, and partly with the nature of 
previous GOLD recommendations. These rec-
ommendations were updated in February 2017, 
indicating the application of LAMA as one of 
the recommended option in cases of category A. 
The LAMA or LABA and LAMA/LABA combined 
treatment is the key of new more individualized 
therapy according to GOLD 2017 [5]. 
According to the opinion of the interviewed 
doctors, disc assures compliance with therapy. The 
disc inhaler is a medium-resistance device. Mahler 
et al indicates that this feature makes the inhaler 
especially beneficial for patients with exacerba-
tions of COPD, resulting in a weakening of muscle 
strength, hyperinflation or hypoxemia. In these 
cases, the use of medium or low-resistance inhal-
ers facilitates adequately low inspiratory flow and 
the overpowering of the resistance generated by 
the conglomerated particles of the medication [16]. 
The doctors surveyed in the present study also 
highlighted the user-friendly characteristics of the 
device, as indicated previously [17–19]. 
The assessment of inhaler use takes approx-
imately five minutes in present study. Also the 
trainers of the Gruppo Educazionale Associ-
azione Italiana Pneumologi Ospedalieri (AIPO) 
spent five minutes on instructing the patient on 
the correct use of the disc device and other dry 
powder inhalers (DPI). However, they needed 
significantly more time to explain the usage of 
the metered-dose inhaler (MDI) [19]. The training 
was found to extend to six minutes among doctors 
reporting the treatment of smaller numbers of 
COPD patients. The AIPO trainers reported old 
age as being one of the most important causes of 
incorrect inhalation [19]. Approximately 20% of 
interviewed doctors test that the device and the 
inhalation are correct during every visit. The 
majority of allergists (97%) and pulmonologists 
(95%) confirm testing in 53% of visits, i.e. every 
two or three visits. Over half of the patient pop-
ulation meet a  specialist every three months. 
Previous studies note that patients still make 
mistakes even after undergoing years of inhaled 
therapy [19]. 
On the contrary, 34% of patients treated by 
GPs do not demonstrate the ability to use the in-
haler correctly. In 38% of cases, spirometry tests 
are performed less than once a year. In addition, 
although spirometry is relatively common in 
specialist clinics, asthma patients rarely perform 
the PEFR (8%) at home. Such management of the 
respiratory conditions can explain the several 
therapeutic decisions made by specialists to mod-
ify the treatment regimens of asthma and COPD 
patients initiated by the GP. 
The Global Asthma Physician and Patient 
Survey (GAPP) conducted in 16 different coun-
tries found that approximately 40% of patients 
in Poland discontinue the treatment based on 
inhaled steroids or modify their dosage due to fear 
of adverse effects, without any previous consul-
tations with attending doctors [20]. Our present 
findings indicate that a  smaller percentage of 
patients discontinue treatment. 
Conclusion
There is a quantitative disproportion between 
the true state of the medical care of asthma and 
COPD patients and the related globally accepted 
standards. Primary health care clinics lack di-
agnostic apparatus (spirometers), and appear to 
lack properly trained medical personnel skilled 
for identification and control of the chronic ob-
structive pulmonary conditions. The contribution 
of nurses in this regard is inadequate and does 
not meet the global standards.
In Poland, the most commonly-used treat-
ment were still individual inhalers but the most 
commonly-used combined therapy was disc in-
haler method involving salmeterol/fluticasone. 
The user-friendly characteristics of the device 
support correct inhalation of the medication, thus 
better control of treatment. 
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